肠道菌群与心血管疾病关系的研究进展

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (599 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Trimethylamine-N-oxide (TMAO), a metabolite of intestinal flora, promotes the occurrence and development of atherosclerosis through the activation of PKC/NF-κB pathway or stimulating foam cell formation. Elevated plasma TMAO can be used as a risk stratification index of poor prognosis in patients with heart failure. Short chain fatty acids, the metabolites of intestinal flora, affect the blood pressure level of host by binding to G-protein-coupled receptors. Meanwhile, intestinal flora can regulate blood pressure by affecting sympathetic nervous, which is the hypothesis of “brain-gut-bone marrow axis”. The abundance and structure of intestinal flora in children with Kawasaki disease have changed. Some special bacteria in the intestine have superantigen activity and can produce heat shock protein. These factors may involve in the occurrence and development of Kawasaki disease by affecting the release of inflammatory factors.

Key words： Intestinal flora Hypertension Atherosclerosis Heart failure Kawasaki disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DOU Wenting1 LI Xiaohui2

Cite this article:

DOU Wenting1 LI Xiaohui2. Research progress of the relationship between intestinal flora and cardiovascular disease[J]. 中国医药导报, 2021, 18(12): 53-56.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I12/53

1] Tamburini S，Shen N，Wu HC，et al. The microbiome in early life：implications for health outcomes [J]. Nat Med，2016，22（7）：713-722.
[2] Sonnenburg JL，B?覿ckhed F. Diet-microbiota interactions as moderators of human metabolism [J]. Nature，2016，535（7610）：56-64.
[3] Hooper LV，Littman DR，Macpherson AJ. Interactions Between the Microbiota and the Immune System [J]. Science，2012，336（6086）：1268-1273.
[4] Human Microbiome Project Consortium. Structure，function and diversity of the healthy human microbiome [J]. Nature，2012，486（7402）：207-214.
[5] Xu H，Wang X，Feng W，et al. The gut microbiota and its interactions with cardiovascular disease [J]. Microb Biotechnol，2020，13（3）：637-656.
[6] Karlsson FH，F?覽k F，Nookaew I，et al. Symptomatic atherosclerosis is associated with an altered gut metagenome [J]. Nat Commun，2012，3（1）：1245.
[7] Jie Z，Xia H，Zhong SL，et al. The gut microbiome in atherosclerotic cardiovascular disease [J]. Nat Commun，2017，8（1）：845.
[8] Ma G，Pan B，Chen Y，et al. Trimethylamine N-oxide in atherogenesis： impairing endothelial self-repair capacity and enhancing monocyte adhesion [J]. Biosci Rep，2017， 37（2）：BSR20160244.
[9] Tang WH，Hazen SL. The contributory role of gut microbiota in cardiovascular disease [J]. J Clin Invest，2014， 124（10）：4204-4211.
[10] Wang Z，Roberts AB，Buffa JA，et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis [J]. Cell，2015，163（7）：1585-1595.
[11] Gregory JC，Buffa JA，Org E，et al. Transmission of ath-erosclerosis susceptibility with gut microbial transplantation [J]. J Biol Chem，2015，290（9）：5647-5660.
[12] Pasini E，Aquilani R，Testa C，et al. Pathogenic Gut Flora in Patients With Chronic Heart Failure [J]. JACC：Heart Failure，2016，4（3）：220-227.
[13] Tang WHW，Li DY，Hazen SL. Dietary metabolism, the gut microbiome, and heart failure [J]. Nat Rev Cardiol，2019，16（3）：137-154.
[14] Lau K，Srivatsav V，Rizwan A，et al. Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases [J]. Nutrients，2017，9（8）：859.
[15] Al-Sadi R，Guo S，Ye D，et al. TNF-α Modulation of Intestinal Epithelial Tight Junction Barrier Is Regulated by ERK1/2 Activation of Elk-1 [J]. Am J Pathol，2013，183（6）：1871-1884.
[16] Niebauer J，Volk HD，Kemp M，et al. Endotoxin and immune activation in chronic heart failure：a prospective cohort study [J]. Lancet，1999，353（9167）：1838-1842.
[17] Organ CL，Otsuka H，Bhushan S，et al. Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure [J]. Circ Heart failure，2016，9（1）：e002314.
[18] Chen K，Zheng X，Feng M，et al. Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide Contributes to Cardiac Dysfunction in Western Diet-Induced Obese Mice [J]. Front Physiol，2017，8：139.
[19] Han H，Zhu J，Zhu Z，et al. p-Cresyl Sulfate Aggravates Cardiac Dysfunction Associated With Chronic Kidney Disease by Enhancing Apoptosis of Cardiomyocytes [J]. J Am Heart Assoc，2015，4（6）：e001852.
[20] Yang T，Santisteban MM，Rodriguez V，et al. Gut Dysbiosis Is Linked to Hypertension [J]. Hypertension，2015，65（6）：1331-1340.
[21] Li J，Yang X，Zhou X，et al. The Role and Mechanism of Intestinal Flora in Blood Pressure Regulation and Hypertension Development [J]. Antioxid Redox Signal，2020， 34（10）：811-830.
[22] Goeser F，Schlabe S，Ruiner CE，et al. Non-invasive fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient presenting with hypertensive disorder post interventionem [J]. Z Gastroenterol，2016，54（10）：1143-1146.
[23] Pluznick JL，Protzko RJ，Gevorgyan H，et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation [J]. Proc Natl Acad Sci U S A，2013，110（11）：4410-4415.
[24] Santisteban MM，Kim S，Pepine CJ，et al. Brain-gut-bone Marrow Axis: Implications for Hypertension and Related Therapeutics [J]. Circ Res，2016，118（8）：1327-1336.
[25] Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation [J]. Gut microbes，2013，5（2）：202-207.
[26] Toral M，Robles-Vera I，de la Visitación N，et al. Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats [J]. Acta Physiol（Oxf），2019，227（1）：e13285.
[27] Takeshita S，Kobayashi I，Kawamura Y，et al. Characteristic profile of intestinal microflora in Kawasaki disease [J]. Acta Paediatr，2002，91（7）：783-788.
[28] 沈男，王莹，王兴翠，等.川崎病对儿童肠道菌群的影响[J].基础医学与临床，2019，39（5）：636-640.
[29] Esposito S，Polinori I，Rigante D. The Gut Microbiota-Host Partnership as a Potential Driver of Kawasaki Syndrome[J]. Front Pediatr，2019，7：124.
[30] Nagata S，Yamashiro Y，Ohtsuka Y，et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease [J]. Immunology，2009，128（4）：511-520.
[31] Kinumaki A，Sekizuka T，Hamada H，et al. Characterization of the gut microbiota of Kawasaki disease patients by metagenomic analysis [J]. Front Microbiol，2015，6：824.
[32] Chen J，Yue Y，Wang L，et al. Altered gut microbiota correlated with systemic inflammation in children with Kawasaki disease [J]. Sci Rep，2020，10（1）：14525.
[33] Gan XT，Ettinger G，Huang CX，et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat [J]. Circ Heart fail，2014，7（3）：491-499.
[34] Galla S，Chakraborty S，Cheng X，et al. Disparate effects of antibiotics on hypertension [J]. Physiol Genomics，2018，50（10）：837-845.